Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

282 13 Applications of CpG Motifs from Bacterial DNA in Cancer Immunotherapy
61 Gao, J. J., Xue, Q., Papasian, C. J. and
Morrison, D. C. Bacterial DNA and
lipopolysaccharide induce synergistic
production of TNF-a through a posttranscriptional
mechanism. J Immunol
2001; 166: 6855±6860.
62 Cowdery, J. S., Chace, J. H.,Yi, A. K.
and Krieg, A. M. Bacterial DNA induces
NK cells to produce IFN-g in vivo
and increases the toxicity of lipopolysaccharides.
J Immunol 1996; 156: 4570±
4575.
63 Zhao, Q., Matson, S., Herrera, C. J.,
et al. Comparison of cellular binding
and uptake of antisense phosphodiester,
phosphorothioate, and mixed
phosphorothioate and methylphosphonate
oligonucleotides. Antisense Res Dev
1993; 3: 53±66.
64 Matson, S. and Krieg, A. M. Nonspecific
suppression of [ 3 H]thymidine incorporation
by ªcontrolº oligonucleotides.
Antisense Res Dev 1992; 2: 325±330.
65 Kenter, A. L. and Tredup, J. High expression
of a 3'±5' exonuclease activity
is specific to B lymphocytes. Mol Cell
Biol 1991; 11: 4398±4404.
66 Liang, H., Nishioka,Y., Reich, C. F.,
Pisetsky, D. S. and Lipsky, P. E. Activation
of human B cells by phosphorothioate
oligodeoxynucleotides. J Clin
Invest 1996; 98: 1119±1129.
67 Hartmann, G.,Weiner, G. J. and
Krieg, A. M. CpG DNA: a potent signal
for growth, activation, and maturation
of human dendritic cells. Proc Natl
Acad Sci USA 1999; 96: 9305±9310.
68 Stein, C. A., Subasinghe, C., Shinozuka,
K. and Cohen, J. S. Physicochemical
properties of phosphorothioate
oligodeoxynucleotides. Nucleic Acids
Res 1988; 16: 3209±3221.
69 Stein, C. A. and Cheng,Y. C. Antisense
oligonucleotides as therapeutic
agents±is the bullet really magical?
Science 1993; 261: 1004±1012.
70 Stein, C. A. and Krieg, A. M. Problems
in interpretation of data derived
from in vitro and in vivo use of antisense
oligodeoxynucleotides [Editorial].
Antisense Res Dev 1994; 4: 67±69.
71 Zhao, Q.,Waldschmidt, T., Fisher, E.,
Herrera, C. J. and Krieg, A. M. Stagespecific
oligonucleotide uptake in mur-
ine bone marrow B-cell precursors.
Blood 1994; 84: 3660±3666.
72 Crooke, R. M. In vitro cellular uptake,
distribution, and metabolism of oligonucleotides.
In: Antisense Research and
Application., ed. S. T. Crooke, Springer,
Berlin 1998; 103±140.
73 Perez, J. R., Li,Y., Stein, C. A., et al.
Sequence-independent induction of
Sp1 transcription factor activity by
phosphorothioate oligodeoxynucleotides.
Proc Natl Acad Sci USA 1994; 91:
5957±5961.
74 Wang, X. Z. and Ron, D. Stress-induced
phosphorylation and activation
of the transcription factor CHOP
(GADD153) by p38 MAP Kinase.
Science 1996; 272: 1347±1349.
75 Burgess, T. L., Fisher, E. F., Ross, S. L.,
et al. The antiproliferative activity of
c-myb and c-myc antisense oligonucleotides
in smooth muscle cells is caused
by a nonantisense mechanism. Proc
Natl Acad Sci USA 1995; 92: 4051±
4055.
76 Fennewald, S. M. and Rando, R. F.
Inhibition of high affinity basic fibroblast
growth factor binding by oligonucleotides.
J Biol Chem 1995; 270:
21718±21721.
77 Guvakova, M. A.,Yakubov, L. A., Vlodavsky,
I., Tonkinson, J. L. and
Stein, C. A. Phosphorothioate oligodeoxynucleotides
bind to basic fibroblast
growth factor, inhibit its binding
to cell surface receptors, and remove it
from low affinity binding sites on extracellular
matrix. J Biol Chem 1995; 270:
2620±2627.
78 Kitajima, I., Unoki, K. and Maruyama,
I. Phosphorothioate oligodeoxynucleotides
inhibit basic fibroblast
growth factor-induced angiogenesis in
vitro and in vivo. Antisense Nucleic Acid
Drug Dev 1999; 9: 233±239.
79 Brown, D. A., Kang, S. H., Gryaznov,
S. M., et al. Effect of phosphorothioate
modification of oligodeoxynucleotides
on specific protein binding.
J Biol Chem 1994; 269: 26801±26805.
80 Khaled, Z., Benimetskaya, L., Zeltser,
R., et al. Multiple mechanisms may
contribute to the cellular anti-adhesive
effects of phosphorothioate oligodeoxy-